The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial
Abstract
CONTEXT: Thiazolidinediones, which are peroxisome proliferator-activated receptor-gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor-gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies. OBJECTIVE: The objective of the study was to determine whether rosiglitazone, a thiazolidinedione, inhibits bone formation. DESIGN: The study was a 14-wk randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted in the general community. PATIENTS: Fifty healthy, postmenopausal women participated in the study. INTERVENTION: Intervention was rosiglitazone 8 mg/d. MAIN OUTCOME MEASURES: The primary end point was biochemical markers of bone formation, and secondary end points were a bone resorption marker and bone mineral density. RESULTS: The osteoblast markers procollagen type I N-terminal propeptide and osteocalcin declined by 13% (P<0.005 vs. placebo) and 10% (P=0.04 vs. placebo), respectively, in the rosiglitazone group. These changes were evident by 4 wk and persisted for the duration of the study. There was no change in the serum beta-C-terminal telopeptide of type I collagen, a marker of bone resorption (P=0.9 vs. placebo). Total hip bone density fell in the rosiglitazone group (mean change from baseline rosiglitazone -1.9%, placebo -0.2%; between-group difference 1.7%, 95% confidence interval 0.6-2.7, P<0.01); lumbar spine bone density fell significantly from baseline values in the rosiglitazone group (P=0.02 vs. baseline) but was not significantly different between groups (mean change from baseline rosiglitazone -1.2%, placebo -0.2%; between-group difference 1.0%, 95% confidence interval -0.2-2.3, P=0.13). CONCLUSIONS: Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U.-I., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 869
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study
Bonds, D. E., Larson, J. C., Schwartz, A. V., Strotmeyer, E. S., Robbins, J., Rodriguez, B. L., Johnson, K. C., & Margolis, K. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0614 · Cited by 611
Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women
Nicodemus, K. K., & Folsom, A. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1192 · Cited by 568
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2005) · Diabetologia · doi:10.1007/s00125-005-1786-3 · Cited by 557
Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.
de Liefde, I. I., van der Klift, M., de Laet, C. E. D. H., van Daele, P. L. A., Hofman, A., & Pols, H. A. P. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1909-1 · Cited by 555
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo
Cornish, J., Callon, K., Bava, U., Lin, C., Naot, D., Hill, B., Grey, A., Broom, N., Myers, D., Nicholson, G., et al. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750405 · Cited by 472
Self-citationInhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B. (2004) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 454
Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444
Lecka-Czernik, B., Moerman, E. J., Grant, D. F., Lehmann, J. M., Manolagas, S. C., & Jilka, R. L. (2002) · Endocrinology · doi:10.1210/endo.143.6.8834 · Cited by 441
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR?2
Lecka-Czernik, B., Gubrij, I., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990901)74:3<357::aid-jcb5>3.0.co;2-7 · Cited by 405
Strotmeyer, E. S., Cauley, J. A., Schwartz, A. V., Nevitt, M. C., Resnick, H. E., Bauer, D. C., Tylavsky, F. A., de Rekeneire, N., Harris, T. B., & Newman, A. B. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1612 · Cited by 377
Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B. R., Kliewer, S. A., Lehmann, J. M., & Morris, D. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09536-7 · Cited by 295
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Self-citationTaylor, B. C., Schreiner, P. J., Stone, K. L., Fink, H. A., Cummings, S. R., Nevitt, M. C., Bowman, P. J., & Ensrud, K. E. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52410.x · Cited by 267
Effects of Low-Dose Prednisone on Bone Metabolism
Ton, F. N., Gunawardene, S. C., Lee, H., & Neer, R. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041125 · Cited by 223
Strotmeyer, E. S., Cauley, J. A., Schwartz, A. V., Nevitt, M. C., Resnick, H. E., Zmuda, J. M., Bauer, D. C., Tylavsky, F. A., de Rekeneire, N., Harris, T. B., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040311 · Cited by 218
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
Sorocéanu, M. A., Miao, D., Bai, X.-Y., Su, H., Goltzman, D., & Karaplis, A. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05723 · Cited by 199
Pei, L., & Tontonoz, P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421311 · Cited by 181
Insulin increases histomorphometric indices of bone formation In vivo
Cornish, J., Callon, K. E., & Reid, I. R. (1996) · Calcified Tissue International · doi:10.1007/bf00369216 · Cited by 164
Self-citationOkazaki, R., Totsuka, Y., Hamano, K., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4258 · Cited by 144
The PROactive study: some answers, many questions
Yki‐Järvinen, H. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67504-6 · Cited by 141
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat
Lazarenko, O. P., Rzońca, S., Suva, L. J., & Lecka‐Czernik, B. (2005) · Bone · doi:10.1016/j.bone.2005.07.008 · Cited by 130
Mbalaviele, G., Abu‐Amer, Y., Meng, A., Jaiswal, R. K., Beck, S., Pittenger, M. F., Thiede, M. A., & Marshak, D. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14388 · Cited by 113
Reid, I. R., Lucas, J., Wattie, D. J., Horne, A. M., Bolland, M. J., Gamble, G. D., Davidson, J. S., & Grey, A. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0573 · Cited by 111
Self-citationComparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone
Reid, I. R., Davidson, J. S., Wattie, D. J., Wu, F., Lucas, J., Gamble, G. D., Rutland, M. D., & Cundy, T. (2004) · Bone · doi:10.1016/j.bone.2004.03.023 · Cited by 106
Self-citationThiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1
Okazaki, R., Toriumi, M., Fukumoto, S., Miyamoto, M., Fujita, T., TANAKA, K., & Takeuchi, Y. (1999) · Endocrinology · doi:10.1210/endo.140.11.7116 · Cited by 105
Cornish, J., Callon, K. E., King, A. R., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e694 · Cited by 102
Self-citationJustesen, J., Mosekilde, L., Holmes, M. C., Stenderup, K., Gasser, J. A., Mullins, J. J., Seckl, J. R., & Kassem, M. S. (2004) · Endocrinology · doi:10.1210/en.2003-1427 · Cited by 89
Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells
Kawaguchi, H., Akune, T., Yamaguchi, M., Ohba, S., Ogata, N., Chung, U., Kubota, N., Terauchi, Y., Kadowaki, T., & Nakamura, K. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0599-2 · Cited by 78
Khan, E., & Abu‐Amer, Y. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(03)00058-1 · Cited by 71
Watanabe, S. T., Takeuchi, Y., Fukumoto, S., Fujita, H. M., Nakano, T., & Fujita, T. (2003) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740300026 · Cited by 56
Okazaki, R., Miura, M., Toriumi, M., et al. (1999) · Endocrine Journal · doi:10.1507/endocrj.46.795 · Cited by 55
Surface-specific effects of a PPARγ agonist, darglitazone, on bone in mice
Li, M., Pan, L. C., Simmons, H. A., Li, Y., Healy, D. R., Robinson, B. S., Ke, H. Z., & Brown, T. A. (2006) · Bone · doi:10.1016/j.bone.2006.04.008 · Cited by 52
Kendall, D. M. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-0711 · Cited by 40
Research works printed but not linked: 3
- Truxillo C, Maximum likelihood parameter estimation with incomplete data. SAS Users Group International Conference, Philadelphia, PA, 2005 (http://www2.sas.com/proceedings/sugi30/111-30.pdf)
- Jennermann, 1995, Effects of thiazolidinediones on bone turnover in the rat, J Bone Miner Res, 10, S241
- Syversen, 2003, PPAR-α agonists increase bone mineral density in female rats, J Bone Miner Res, 18, S42
Cited by
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Choi, J. H., Banks, A. S., Kamenecka, T. M., Busby, S. A., Chalmers, M. J., Kumar, N., Kuruvilla, D. S., Shin, Y., He, Y., Bruning, J. B., et al. (2011) · Nature · doi:10.1038/nature10383 · Cited by 536
Metadata
- Authors
- Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-04-01
- Volume
- 92
- Issue
- 4
- Pages
- 1305-1310
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1976942305
- Cited by
- 401
- References
- 42
- FWCI
- 49.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.